Amarin Corp Plc (AMRN)

[sstyles]

That's on JT and management to make the case to Wall Street. They have been relatively silent since GSK v. Teva ruling came out.

JT needs to connect the dots for investors.

Of course Teva is going to ask for an en banc hearing. So this could stretch out well into 2021 and this does not factor in a likely appeal to the Supreme Court.

What does this all mean? What generics thought they won has been completely halted so long as the GSK v. Teva case is still pending in the courts. Why?

DAMAGES. There's not a CEO out there who is taking material steps until the case is fully resolved. The longer the better for Amarin. Delays in the Teva case are to Amarin's advantage because it keeps generics at bay.

Why is Amarin so silent on this? I don't know.